# Morning Run Log

A running record of what each scheduled morning agent attempted. Each new run MUST read this file first and avoid repeating prior directions.

## 2026-06-23

**Direction:** drug-pool
**Angle:** EZH2 histone-methylation axis (KDM6A/B inhibition by succinate), autophagy survival dependency, and NAD⁺/NAMPT synthetic lethality
**Summary:** Added three drugs covering three mechanistically distinct angles absent from the existing pool: tazemetostat (EZH2 inhibitor, FDA-approved for SMARCB1-null sarcoma; H3K27me3 accumulates in SDH-deficient tumors when succinate blocks KDM6A/B demethylases), hydroxychloroquine (lysosomal autophagy inhibitor, fills the existing autophagy-survival pathway which had no drugs assigned), and daporinad/FK866 (NAMPT inhibitor; elevated ROS from Complex II dysfunction drives chronic PARP1 activation consuming NAD+, creating NAMPT dependency). Added EZH2, BECN1, and NAMPT as new targets, added a NAD+ metabolism pathway, and updated the SDH biology context to cover these mechanisms.
**PR:** morning/2026-06-23-ezh2-autophagy-nampt

## 2026-07-01

**Direction:** drug-pool
**Angle:** FGFR1 autocrine loop via epigenetic insulator loss (FGF3/FGF4 de-repression by CTCF silencing downstream of CpG hypermethylation)
**Papers added:** 3 (PMIDs 42191879, 42181244, 41928014)
**Summary:** PubMed scan found a Phase 2 trial of rogaratinib (pan-FGFR inhibitor) in SDH-deficient GIST published in Nature Medicine May 2026 (PMID 42191879), showing 41.7% ORR and median PFS of 31 months — the first prospective evidence of targeted therapy for SDH-deficient GIST predicated on an epigenetic mechanism. Added rogaratinib as a drug candidate (evidence_score 72, status clinical_trial), the `fgfr-signaling` pathway, and FGFR1 as a target. Also created `src/data/papers.ts` (curated papers file, previously absent) and added 3 recent papers including the neddylation CRISPR screen (PMID 42181244) and SSTR2 profiling in SDHB-deficient PPGL (PMID 41928014) as notes for future investigation. The neddylation vulnerability (pevonedistat/MLN4924) and SSTR2-selective agonists were not added to the drug pool as they need more evidence — flagged as future directions.
**PR:** morning/2026-07-01-fgfr-insulator-rogaratinib
